TELA Bio, Inc.

NasdaqGM:TELA

Sector

🏥 Health Care

Industries

💻 Telehealth

🧬 Biotechnology

🧱 Cement

🔬 Chemicals & Advanced Materials

🔬 Clinical Trials

🏗 Construction Materials

Location

United States

Market Cap

USD 65.27 M

Share Price

USD 1.65

Avg Daily Volume

269,371

Change (1 day)

-1.20%

Change (1 year)

-68.15%

Change (YTD)

-45.36%

TELA Bio, Inc. Net Income for the Trailing 12 Months (TTM) ending March 31, 2025: USD -43.44 M

TELA Bio, Inc. Net Income is USD -43.44 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 7.81% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

TELA Bio, Inc. Net Income for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -40.30 M, a -17.94% change year over year.
TELA Bio, Inc. Net Income for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -49.11 M, a 32.65% change year over year.
TELA Bio, Inc. Net Income for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -37.02 M, a 24.60% change year over year.
TELA Bio, Inc. Net Income for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -29.71 M, a 25.47% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)

NasdaqGM: TELA

TELA Bio, Inc.

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway
Employees	209
Sector	🏥 Health Care
Industries Telehealth 🧬 Biotechnology 🧱 Cement 🔬 Chemicals & Advanced Materials 🔬 Clinical Trials 🏗 Construction Materials

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.